A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line.
about
A Single-use Strategy to Enable Manufacturing of Affordable BiologicsAdvances in recombinant antibody manufacturingVery high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor™. Part I. Effect of the cell density on the process.Development of high-productivity, strong cation-exchange adsorbers for protein capture by graft polymerization from membranes with different pore sizes.Recent developments in membrane-based separations in biotechnology processes: review.Recent advances in technology supporting biopharmaceutical production from mammalian cells.Identifying and engineering promoters for high level and sustainable therapeutic recombinant protein production in cultured mammalian cells.Boronic acid-modified magnetic materials for antibody purificationNext generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles.Designing cell lines for viral vaccine production: Where do we stand?Downstream Processing Technologies/Capturing and Final Purification : Opportunities for Innovation, Change, and Improvement. A Review of Downstream Processing Developments in Protein Purification.The role of more than 40 years of improvement in protein A chromatography in the growth of the therapeutic antibody industry.The translation of cell-based therapies: clinical landscape and manufacturing challenges.Trends in Upstream and Downstream Process Development for Antibody Manufacturing.Continuous precipitation of IgG from CHO cell culture supernatant in a tubular reactor.Economics of recombinant antibody production processes at various scales: Industry-standard compared to continuous precipitation.Recent Advances in Next Generation Snakebite Antivenoms
P2860
Q26738464-AC80D1AD-897A-4993-B0FD-5606F8BFCF73Q26764949-5E156DAC-E63C-45FC-B2C0-844737CCDE06Q30450136-C6A40693-F4E7-4FB2-9675-76B7128179C4Q34486515-B11C2749-0F6A-44B0-905E-628224E8FBA9Q37941805-563C3E5B-ABEF-49C3-BD44-C3D9A3D28817Q38050998-122B3414-B458-4EC7-A8BE-6BF12810B2E9Q38204917-CCC2780B-ACAE-4A2F-BD50-764C86D47EDAQ38311042-F7CE2253-CDDB-425C-A9B7-399C0EF831C2Q38423724-E562622F-F36B-4333-A490-836CA7FF7732Q38436738-057FEAB5-819A-4D22-9EF5-24491B471F42Q38631194-359B203C-790B-478C-B4E5-4933C7887C3FQ38807986-4A7C0741-8792-429A-A07C-82657A3B5786Q39063831-D278203D-6565-4E3A-89DC-3AA3AED4001EQ47843398-32D092A6-18D4-4513-9D62-14A13D7E24FBQ51744054-DC86E024-7AB1-4C6D-B122-69D3A89790BCQ53580907-54EC7F3B-3AF9-47C5-AFFD-A0C3CE223468Q56889475-52ADDA9C-D173-47FA-9E05-9CDFAFF09938
P2860
A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A single-use purification proc ...... d in a PER.C6 human cell line.
@en
A single-use purification proc ...... d in a PER.C6 human cell line.
@nl
type
label
A single-use purification proc ...... d in a PER.C6 human cell line.
@en
A single-use purification proc ...... d in a PER.C6 human cell line.
@nl
prefLabel
A single-use purification proc ...... d in a PER.C6 human cell line.
@en
A single-use purification proc ...... d in a PER.C6 human cell line.
@nl
P2093
P2860
P356
P1476
A single-use purification proc ...... d in a PER.C6 human cell line.
@en
P2093
Blanca Lain
Emily Schirmer
Gregory Zarbis-Papastoitsis
Michael Kuczewski
P2860
P356
10.1002/BIOT.201000292
P577
2011-01-01T00:00:00Z